International Stem Cell Corporation to Present Six-Month Results of Neural Stem Cell Transplantation for Parkinson’s … – GlobeNewswire (press release)
|
International Stem Cell Corporation to Present Six-Month Results of Neural Stem Cell Transplantation for Parkinson’s …
GlobeNewswire (press release) CARLSBAD, Calif., Nov. 08, 2017 (GLOBE NEWSWIRE) — International Stem Cell Corporation (OTCQB:ISCO), a California-based clinical stage biotechnology company developing stem cell-based therapies and biomedical products, announced today that its … |
Endpoints News |
Amgen bets on stem cell company Fortuna Fix in $25M round
Endpoints News The company says it’s reproduced this phenomena in test tubes by starting with regular old multipotent stem cells, which can be taken from any tissue (hair, skin, bone marrow, etc.) and re-engineered into neural stem cells. There’s a name for this kind … Amgen makes regenerative medicine play, backing $25M Fortuna …FierceBiotech |
Muscular Dystrophy News |
FDA Clears IND Application for Micro-dystrophin Gene Therapy Program to Treat Duchenne
Muscular Dystrophy News The U.S. Food and Drug Administration (FDA) has cleared an investigational new drug application for a micro-dystrophin gene therapy program by Sarepta Therapeutics and Nationwide Children’s Hospital, in clinical development for Duchenne muscular … |
CNET |
Gene editing and ‘playing God:’ How far should we go?
CNET “Playing God,” a new CBSN Originals documentary that airs Wednesday night, explores both the potential and possible pitfalls of CRISPR, a gene-editing technology developed in 2012. It’s an exciting breakthrough that could revolutionize how we grow … |
STAT |
CAR T-cell therapy approved for B-cell lymphomas may save ‘thousands of lives’ in next few years
Healio The agency on Oct. 18 approved axicabtagene ciloleucel (Yescarta; Kite, Gilead), a chimeric antigen receptor (CAR) T-cell therapy for patients with relapsed or refractory large B-cell lymphoma who underwent two or more lines of systemic therapy. Revolutionary new cancer therapies come with big risks. Drug makers must be preparedSTAT Cellectis gets FDA go-ahead to restart fatal CAR–T trialpharmaphorum |
STAT |
Will tiny OncoSec break out with promising melanoma immunotherapy study results?
STAT he addition of an experimental immunotherapy from OncoSec Medical (ONCS 1) to Merck’s (MRK 2) checkpoint inhibitor Keytruda is shrinking tumors in almost half of the skin cancer patients treated in a small clinical trial, according to updated results … OncoSec Announces Positive Updated Long-Term Follow-Up Data from Phase 2 Trial of ImmunoPulse® IL-12 in …Markets Insider |